10 Results for "

retinal edema

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "retinal edema" in MCE Product Catalog:

  • Targets Recommended:
8
8 Cited Publications
Cat. No.: HY-14648A
CAS No.: 1177-87-3
Purity:  99.84%
Synonyms: Dexamethasone 21-acetate; Hexadecadrol acetate
Research Areas:  

Inflammation/Immunology

Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery .
loading...
    loading...
Cat. No.: HY-P99116
CAS No.: 1607793-29-2
Synonyms: RG7716; RO-6867461
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
loading...
    loading...
Cat. No.: HY-145633
CAS No.: 2568358-31-4
Purity:  98.52%
Synonyms: OPT 302; VGX-300

Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
loading...
    loading...
Cat. No.: HY-P990012
CAS No.: 2744320-12-3
Synonyms: EBI-031

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Vamikibart (EBI-031) is a humanized IgG2κ monoclonal antibody targeting IL-6, with high binding affinity for IL-6 and the IL-6/IL-6R complex. Vamikibart reduces central retinal thickness, resolves intraretinal and subretinal foveal fluid, and decreases the levels of intraocular inflammatory markers. Vamikibart can be used in studies of uveitic macular edema (UME) secondary to non-infectious uveitis .
loading...
    loading...
Cat. No.: HY-136642
CAS No.: 807-38-5
Purity:  99.66%
Research Areas:  

Inflammation/Immunology

Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
loading...
    loading...
Cat. No.: HY-P991293

Target:  

c-Kit

Research Areas:  

Metabolic Disease

NN-2101 is a human monoclonal antibody (mAb) targeting c-Kit/CD117. NN-2101 is used in the research of retinal disorders and diabetic macular edema.
loading...
    loading...
Cat. No.: HY-178919
CAS No.: 2996841-28-0
N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa .
loading...
    loading...
Cat. No.: HY-W423707
CAS No.: 1001341-27-0
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

TG 100948 is a dual VEGFR and tyrosine kinase Src inhibitor. TG 100948 reduces retinal edema and retinal thickening, and eliminates bullous edema cysts in a rat model of ischemic retinal vein occlusion. TG 100948 can be used for the research of ischemic retinal vein occlusion .
loading...
    loading...
Cat. No.: HY-136642R
CAS No.: 807-38-5
Fluocinolone (Standard) is the analytical standard of Fluocinolone (HY-136642). This product is intended for research and analytical applications. Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
loading...
    loading...
Cat. No.: HY-P992126
CAS No.: 3059389-31-7
Synonyms: EYE-103; MK-3000

Target:  

Wnt

Research Areas:  

Neurological Disease

Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4. Remigromig activates the Wnt/β-catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation and restores blood-retinal barrier function. Administered via intravitreal injection, Remigromig reduces retinal vascular leakage, and demonstrates improvements in best-corrected visual acuity and reductions in retinal thickness in studies of diabetic macular edema. Remigromig can be used for research related to macular degeneration .
loading...
    loading...